H. yanyuanensis LDTI Family Expansion (2025)
Lineage-specific expansion of the leech-derived tryptase inhibitor (LDTI) family in Haemadipsa yanyuanensis terrestrial leech — Lin 2025.
Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Lineage-specific expansion of the leech-derived tryptase inhibitor (LDTI) family in Haemadipsa yanyuanensis terrestrial leech — Lin 2025.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
LDTI family expansion is documented at genome / phylogenetic level only; functional characterization pending. No FDA-approved derivative; H. yanyuanensis is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Source species
- Haemadipsa yanyuanensis
- Discovered
- 2025 · Lin Y et al.
Biological Targets
- → mast-cell tryptase (predicted by LDTI Kazal-domain homology)
Key Citations
- Lin Y et al. (2025), BMC Genomics · PMID 41469844
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.